modelProtamine
Extends from Pharmacolibrary.Drugs.ATC.V.V03AB14.
Information
| name: | Protamine | |
| ATC code: | V03AB14 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.27 | L |
| clearance: | 56 | mL/min |
| other parameters in model implementation | ||
Protamine is a cationic polypeptide used clinically to reverse the anticoagulant effects of heparin, particularly during surgeries such as cardiac and vascular procedures. It acts by binding to heparin to form a stable complex, thereby neutralizing its anticoagulant activity. Protamine is used in hospital settings and is currently approved for clinical use.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult male volunteers after intravenous administration of protamine sulfate.
References
Jia, Z, et al., & Hou, X (2015). Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. Journal of translational medicine 13 45–None. DOI:10.1186/s12967-015-0404-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25638272
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)